ArticleFrontiers in microbiology2026
Genomic determinants of antifungal activity of
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Materials and methods: In the current study, we employed an integrated approach that involved physiological and biochemical characterization, genome mining, comparative genomics, and evolutionary analysis to elucidate the specific genomic determinants underlying the antifungal activity exhibited by STM-2, a novel Results and discussion: Initial physiological and biochemical characterization, complemented by enzymatic screening, revealed the secretion of antifungal hydrolytic enzymes, including protease, CMCase, pectinase and xylanase, which actively play a role in fungal growth inhibition and fungal cell wall degradation. To elucidate the molecular basis of this activity, a wholegenome sequence was obtained and annotated, revealing a typical high-GC (71%) linear chromosome. Genome mining using antiSMASH predicted an extensive repertoire of 52 biosynthetic gene clusters (BGCs), encompassing type I and II PKS, NRPS, and hybrid PKS-NRPS systems, RiPPs, siderophores, terpenes, and diverse tailoring enzymes (P450s, glycosyltransferases, halogenase candidates). Again, we identified genes tentatively responsible for antifungal activity, including chitinases, β-1,3-glucanases, xylanses, pectinases, and proteases. Comparative pangenomic analysis, supported by high-resolution Average Nucleotide Identity (ANI) and digital DNA-DNA hybridization (dDDH) scores, revealed the evolutionary uniqueness of the strain, identifying an accessory genome containing unique genes specifically associated with specialized antifungal activity. Further in silico structural analysis of these unique gene products using AlphaFold2 yielded threedimensional protein models with very high pLDDT scores, providing high-confidence structural evidence for their specialized functional roles. Collectively, these results provide a comprehensive understanding of the genomic determinants required for potent biocontrol activity, positioning STM-2 as a promising candidate for biocontrol and further research in biotechnological applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.